My thoughts for tonight FSD Pharma Unbuzzd Celly Nu $HUGE -
Phase Trials: Yes, FSD Pharma has had multiple phase trials. This is actually normal for any biotech company that's working on developing new treatments. It's a sign of ongoing research and development, not failure.
-
Shares to Creditors: Issuing shares to manage debt is a strategic decision. Many companies do this, especially in the biotech sector. Dilution might impact share price in the short term, but it’s a part of managing growth and investment in research.
-
Revenue: Biotech companies often take years before they start generating significant revenue. The focus is on developing treatments that can potentially bring in substantial future revenue.
-
Phase Progression: Getting from Phase 1 to Phase 3 is a rigorous process that requires significant investment. It's not unique to FSD Pharma; it's the nature of the industry. Claiming "it'll never ever happen" ignores how biotech development works.
-
Leadership and Partnerships: Changes in board members and partnerships are part of the business world. Successful companies evolve and adapt their leadership to navigate different phases of growth.
-
Product Development: Developing and bringing new products to market is a lengthy process. It's not surprising that some products take time to generate significant revenue or visibility.
-
Financial Performance: Writing off unsellable inventory is a standard practice to maintain accurate financial records. It’s a responsible action, not a sign of failure.
-
Long-term Vision: Predicting bankruptcy without substantial evidence is quite dramatic. Biotech investing is about understanding long-term potential, not short-term fluctuations.
It's clear you've got some strong opinions, but let's break down your claims with some recent facts about FSD Pharma:
-
Phase Trials and Progress: FSD Pharma recently received approval from the human ethics review committee (HREC) in Australia for a Phase 1 trial of Lucid-21-302, a first-in-class neuroprotective compound aimed at treating multiple sclerosis (MS). This approval is a significant milestone, demonstrating that FSD Pharma is making concrete progress in its clinical development.
-
Strategic Partnerships: FSD Pharma has entered into an exclusive option agreement with the University of Southern California (USC) to evaluate innovative dietary supplement technology. This partnership underscores FSD Pharma's commitment to advancing its research through collaboration with renowned institutions, not merely "throwing darts."
-
Product Launch - unbuzzd™: FSD Pharma is preparing to launch unbuzzd™, a blend designed to expedite alcohol metabolism and enhance mental alertness. Partnering with industry leaders from Celsius Holdings and The Coca-Cola Company, FSD Pharma is poised to bring a scientifically backed product to market, showcasing their ability to execute and innovate.
-
Financial Management and Stability: While you mention the issuance of shares, it's crucial to understand that this is a common and strategic financial decision, especially in the biotech industry. FSD Pharma has a substantial tax loss carry forward of approximately CAD$130 million, which can be used to offset future tax obligations, enhancing financial stability.
-
Ownership and Royalties: FSD Pharma retains ownership of 25.71% of Celly Nutrition Corp., which markets unbuzzd™, and benefits from a structured royalty agreement. This not only diversifies revenue streams but also provides long-term financial benefits.
-
Innovative Pipeline: Lucid-21-302 is a patented new chemical entity that has shown promise in preclinical models for preventing and reversing myelin degradation, a critical aspect of treating MS. This indicates a focused and strategic approach to developing treatments for significant health challenges.
-
Strategic Investments: FSD Pharma maintains a portfolio of strategic investments secured by residential or commercial property through its wholly-owned subsidiary, FSD Strategic Investments Inc. This diversified investment strategy strengthens the company's financial foundation.
-
Ongoing Developments: The company's continued advancements, such as the recent HREC approval and the launch of unbuzzd™, illustrate a commitment to innovation and progress. These are not signs of a company "doing absolutely nothing" but rather of one actively pursuing growth and development.
Your predictions of bankruptcy and misuse of funds overlook the strategic partnerships, product developments, and financial maneuvers that FSD Pharma is actively engaging in. Instead of making broad, unfounded statements, it's essential to recognize the actual steps the company is taking to create value and advance its mission.